Elicio Therapeutics
Elicio Therapeutics, a biotechnology company based in Cambridge, Massachusetts, specializes in developing innovative immunotherapies for treating aggressive cancers. Its proprietary Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, amplifying the body's immune response against cancer.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
1 past transactions
Angion
Acquisition in 2023
Angion Biomedica Corp. is a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule therapeutics aimed at treating acute organ injuries and fibrotic diseases, particularly focusing on renal conditions. The company is advancing several product candidates, including BB3, which is undergoing phase 3 trials for delayed graft function following kidney transplants and phase 2 trials for acute kidney injury related to open-heart surgery. Another key candidate, ANG-3070, is an orally bioavailable fibrokinase inhibitor designed for chronic kidney disease and polycystic kidney disease. Additionally, Angion is exploring other compounds targeting renal disease and fibrosis, such as ANG-3586 and ANG-4021. Founded in 1998, Angion is headquartered in San Francisco, California, with research facilities in New York and clinical operations in Boston.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.